Gboxin Clinical Trials

Size	Price	Qty
2mg	USD 179
5mg	USD 357

Clinical Trials

Multiple clinical trials evaluate Gboxin for aggressive central nervous system malignancies, specifically targeting glioblastoma multiforme, diffuse midline glioma with H3 K27M mutations, gliosarcoma, and diffuse brainstem glioma. Sponsored by Andrey Petrov, this research includes a Phase I pilot study and an expanded access program. Recruitment for these studies is currently designated as suspended or no longer available, reflecting early-phase clinical exploration of this compound in high-grade gliomas.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06806228	SUSPENDED	Glioblastoma Multiforme; Diffuse Midline Glioma, H3 K27M-Mutant; Gliosarcoma; Giant Cell Glioblastoma; GBM	Petrov, Andrey	2026-05-20	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-06-03)

Check the Gboxin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Gboxin selectively binds and inhibits mitochondrial F0F1 ATP synthase, thereby impairing oxidative phosphorylation and disrupting cellular ATP production. This metabolic suppression selectively arrests the growth of primary glioblastoma cells while sparing non-cancerous neural cells, rendering it clinically relevant for targeting metabolic vulnerabilities in glioblastoma multiforme and diffuse midline gliomas.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).